CTLA4 and glioblastoma: Preclinical studies in the immunogenic GL261 syngeneic GBM mouse model have demonstrated the efficacy of targeting T cell immune-checkpoints, including CTLA-4, PD-1, PD-L1 and PD-L2 as monotherapies or in combination with radiotherapy [52].